Healy, Fiona M, Prior, Ian A 
ORCID: 0000-0002-4055-5161 and MacEwan, David J ORCID: 0000-0002-2879-0935
(2022)
The importance of Ras in drug resistance in cancer.
BRITISH JOURNAL OF PHARMACOLOGY, 179 (12).
pp. 2844-2867.
|
Text
Healy et al BJP clean.pdf - Author Accepted Manuscript Download (1MB) | Preview |
Abstract
In this review, we analyse the impact of oncogenic Ras mutations in mediating cancer drug resistance and the progress made in the abrogation of this resistance, through pharmacological targeting. At a physiological level, Ras is implicated in many cellular proliferation and survival pathways. However, mutations within this small GTPase can be responsible for the initiation of cancer, therapeutic resistance and failure, and ultimately disease relapse. Often termed "undruggable," Ras is notoriously difficult to target directly, due to its structure and intrinsic activity. Thus, Ras-mediated drug resistance remains a considerable pharmacological problem. However, with advances in both analytical techniques and novel drug classes, the therapeutic landscape against Ras is changing. Allele-specific, direct Ras-targeting agents have reached clinical trials for the first time, indicating there may, at last, be hope of targeting such an elusive but significant protein for better more effective cancer therapy. LINKED ARTICLES: This article is part of a themed issue on New avenues in cancer prevention and treatment (BJP 75th Anniversary). To view the other articles in this section visit http://onlinelibrary.wiley.com/doi/10.1111/bph.v179.12/issuetoc.
| Item Type: | Article |
|---|---|
| Uncontrolled Keywords: | acquired resistance, cancer stem cells, Drug resistance, intrinsic resistance, MAPK, PI3K |
| Depositing User: | Symplectic Admin |
| Date Deposited: | 09 Mar 2021 10:54 |
| Last Modified: | 18 Jan 2023 22:57 |
| DOI: | 10.1111/bph.15420 |
| Open Access URL: | https://doi.org/10.1111/bph.15420 |
| Related URLs: | |
| URI: | https://livrepository.liverpool.ac.uk/id/eprint/3116829 |
Dimensions
Dimensions
